Research programme: COMT inhibitors - CeNeS Pharmaceuticals

Drug Profile

Research programme: COMT inhibitors - CeNeS Pharmaceuticals

Latest Information Update: 08 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CeNeS Pharmaceuticals
  • Developer Certara; PAION
  • Class Small molecules
  • Mechanism of Action Catechol-O-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Parkinson's disease; Schizophrenia

Most Recent Events

  • 23 Jun 2008 CeNeS Pharmaceuticals has been acquired by PAION
  • 27 Jul 2007 Preclinical development is ongoing
  • 15 Sep 2006 CeNeS Pharmaceuticals and Tripos have extended their research agreement to co-develop COMT inhibitors in the US for Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top